文献速递胸部肿瘤

一线度伐利尤单抗治疗PD-L1阳性、体能状态评分为2的晚期非小细胞肺癌患者:多中心单臂II期SAKK 19/17试验主要分析

First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17.
PubMed 文献 · Eur J Cancer · 2024-02-05

该多中心单臂II期试验纳入48例PD-L1阳性(肿瘤比例评分≥25%)、体能状态评分为2的晚期非小细胞肺癌患者,接受每四周一次度伐利尤单抗1500 mg治疗。主要终点6个月总生存率为60%(95%CI:45-74%),中位总生存期8.5个月(95%CI:4.4-16.7),治疗相关≥3级不良事件见于9例(19%)。结论认为该方案早期致死事件较多,排除≥3级呼吸困难患者后6个月总生存期较好且毒性可接受,度伐利尤单抗可作为不适合铂类双药化疗且经过良好筛选的PS2患者替代单药化疗的选择。

要点

  • 6个月总生存率60%(95%CI:45-74%),中位总生存期8.5个月(95%CI:4.4-16.7)。
  • 治疗相关≥3级不良事件见于9例(19%),包括1例5级结肠穿孔。
  • 前5周内发生7例早期致死事件,其中4/7(57%)为晚期症状性原发肺肿瘤患者的呼吸衰竭。

核心结论

  • 一线度伐利尤单抗治疗PD-L1阳性、PS2的晚期NSCLC患者早期致死事件较多,排除≥3级呼吸困难患者后6个月OS较好且毒性可接受,度伐利尤单抗可作为经过良好筛选、不适合铂类双药化疗的PS2患者替代单药化疗的选择。

研究设计与样本

  • 多中心、单臂、II期试验(SAKK 19/17),纳入48例PD-L1阳性(肿瘤比例评分≥25%)、PS2的晚期NSCLC患者。

主要发现

  • 中位随访23.3个月(95%CI:14.3-28.6),6个月OS为60%(95%CI:45-74%),中位OS为8.5个月(95%CI:4.4-16.7)。
  • 客观缓解率为17%(95%CI:8-30%),中位无进展生存期为2.5个月(95%CI:1.8-7.1)。
  • 分析时观察到33例死亡,治疗前5周内发生7例早期致死事件,均认为与治疗无关,其中4/7(57%)为晚期症状性原发肺肿瘤患者的呼吸衰竭。
  • 排除≥3级呼吸困难患者后,又发生3例早期致死事件。
  • 治疗相关≥3级不良事件见于9例(19%),包括1例5级结肠穿孔、4例(8%)结肠炎、3例(6%)脂肪酶升高和2例(4%)肝炎。

关键数值与推荐

  • PD-L1阳性定义为肿瘤比例评分≥25%。
  • 度伐利尤单抗剂量为1500 mg,每四周一次。

临床怎么用

  • 作者认为,对于不适合铂类双药化疗且经过良好筛选的PS2患者,度伐利尤单抗可作为替代单药化疗的选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The safety and efficacy of first-line durvalumab in PS2 patients with advanced NSCLC is unknown. Here, we present the primary analysis of first-line durvalumab in PS2 patients, unsuitable for combination chemotherapy. METHODS: In this single-arm, multicenter, phase II trial patients with PD-L1 positive (tumor proportional score ≥25%), advanced NSCLC with PS2, received four-weekly durvalumab 1500 mg. The primary endpoint was overall survival (OS) at 6 months. RESULTS: Forty-eight patients were included. Median follow-up was 23.3 months (95% CI: 14.3-28.6). OS at 6 months was 60% (95% CI: 45-74%). Median OS was 8.5 months (95%CI: 4.4-16.7). Objective response rate and median progression free survival were 17% (95% CI: 8-30%) and 2.5 months (95% CI: 1.8-7.1), respectively. Thirty-three deaths were observed at the time point of the analysis. Seven early fatal events considered not treatment-related occurred during the first 5 weeks of treatment. Four out of the first 7 early fatal events (4/7; 57%) were respiratory failure in patients with advanced symptomatic primary lung tumors. Three more early fatal events occurred after exclusion of patients with grade ≥ 3 dyspnea. Treatment-related AEs ≥G3 were reported in 9 patients (19%) and included colonic perforation in one patient (grade 5), colitis in 4 patients (8%), increased lipase in 3 patients (6%), and hepatitis in 2 patients (4%). CONCLUSIONS: First-line durvalumab in PS2 patients with advanced PD-L1 positive NSCLC results in a high number of early fatal events. When patients with grade ≥ 3 dyspnea are excluded a promising 6-month OS with an acceptable toxicity profile can be observed. Durvalumab could be an option instead of single agent chemotherapy for PS2 patients who are not candidates for platinum doublet chemotherapy provided they are well selected.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Mark M, Froesch P, Gysel K, et al. First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17. Eur J Cancer. 2024. PMID: 38330766. doi:10.1016/j.ejca.2024.113600

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。